SCHEMBL935820

SCHEMBL935820

CC(C)(O)CC(N)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.46
PTGS1 P23219 2/20 0.44
SLC7A11 Q9UPY5 1/20 0.44
GRIK1 P39086 8/20 0.44
SLC1A2 P43004 7/20 0.41
SLC1A3 P43003 6/20 0.41
SLC1A1 P43005 6/20 0.41
GRIK2 Q13002 6/20 0.41
GRM1 Q13255 2/20 0.41
GRM2 Q14416 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
GRM8 O00222 1/20 0.41
GRM6 O15303 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GSR P00390 1/20 0.41
CYP1A2 P05177 1/20 0.41
GRM5 P41594 1/20 0.41
GRIA1 P42261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31215074 1.00 SLC7A5 (0.46) SLC7A5PTGS1SLC7A11GRIK1SLC1A2
SCHEMBL1236556 1.00 SLC7A5 (0.46) SLC7A5PTGS1SLC7A11GRIK1SLC1A2
SCHEMBL25661908 0.85 SLC7A5 (0.46) SLC7A5PTGS1SLC7A11GRIK1SLC1A2
SCHEMBL197117 0.82 SLC7A5 (0.48) SLC7A5PTGS1SLC7A11GRIK1SLC1A2
SCHEMBL196695 0.82 SLC7A5 (0.48) SLC7A5PTGS1SLC7A11GRIK1SLC1A2
SCHEMBL197139 0.82 SLC7A5 (0.48) SLC7A5PTGS1SLC7A11GRIK1SLC1A2
SCHEMBL1332891 0.81 GRIK1 (0.46) SLC7A5PTGS1SLC7A11GRIK1SLC1A2
SCHEMBL127215 0.81 GRIK1 (0.46) SLC7A5PTGS1SLC7A11GRIK1SLC1A2
Hydrochloric Acid SCHEMBL18770586 0.80 SLC7A5 (0.46) SLC7A5PTGS1SLC7A11GRIK1SLC1A2
SCHEMBL2424261 0.80 SLC7A5 (0.46) SLC7A5PTGS1SLC7A11GRIK1SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3367999-A1 FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS The Procter and Gamble Company (US) 2018-09-05 EP claimed
US-20170121633-A1 Fragrance Compositions Comprising Ionic Liquids THE PROCTER & GAMBLE COMPANY 2017-05-04 US claimed
WO-2017075299-A1 FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS THE PROCTER & GAMBLE COMPANY (US) 2017-05-04 WO claimed
US-7674486-B2 Synergistic composition for the treatment of diabetes mellitus INDUS BIOTECH PVT. LTD. (IN) 2010-03-09 US claimed
EP-1638586-B1 A SYNERGISTIC COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS INDUS BIOTECH PVT LTD (IN) 2008-03-26 EP claimed
EP-1763359-A2 USE OF THE PREGNANE GLYCOSIDES IN THE TREATMENT/MANAGEMENT OF OBESITY, OBESITY-RELATED AND OTHER DISORDERS Rajendran, Ramaswany (IN) 2007-03-21 EP claimed
US-20070031521-A1 Synergistic composition for the treatment of diabetes mellitus INDUS BIOTECH PVT. LTD. (IN) 2007-02-08 US claimed
US-20060292252-A1 Synergistic composition for the treatment of diabetes mellitus INDUS BIOTECH PVT. LTD. (IN) 2006-12-28 US claimed
WO-2005102371-A2 USE OF THE PREGNANE GLYCOSIDES IN THE TREATMENT/MANAGEMENT OF OBESITY, OBESITY-RELATED AND OTHER DISORDERS RAJENDRAN RAMASWAMY (IN) 2005-11-03 WO claimed
US-20230151394-A1 BIOLOGIC SYNTHESIS OF DIOLS FROM AMINO ACIDS Taizhou Simplu Technology Co., Ltd. (CN) 2023-05-18 US disclosed
US-20230151394-A1 BIOLOGIC SYNTHESIS OF DIOLS FROM AMINO ACIDS Taizhou Simplu Technology Co., Ltd. (CN) 2023-05-18 US disclosed
US-20230151394-A1 BIOLOGIC SYNTHESIS OF DIOLS FROM AMINO ACIDS Taizhou Simplu Technology Co., Ltd. (CN) 2023-05-18 US disclosed
EP-4127197-A1 BIOLOGIC SYNTHESIS OF DIOLS FROM AMINO ACIDS Taizhou Simplu Technology Co., Ltd. (CN) 2023-02-08 EP disclosed
CN-115698309-A Biosynthesis of diols from amino acids 台州至简科技有限责任公司 2023-02-03 CN disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
CN-101048179-A Compositions and methods for activating protein synthesis and deactivating catabolic processes in skeletal muscle MTOR FORMULATIONS LTD (CA) 2007-10-03 CN disclosed
CN-1946847-A Process for producing dipeptide KYOWA HAKKO KOGYO KK (JP) 2007-04-11 CN disclosed
CN-1938425-A Process for producing dipeptide KYOWA HAKKO KOGYO KK (JP) 2007-03-28 CN disclosed
US-5470879-A 4-hydroxyisoleucine or lactone thereof LABORATORIES MONAL (FR) 1995-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121633-A1 Fragrance Compositions Comprising Ionic Liquids CUTA, TRPA1, POLR1C SLC7A5 3031/4885PTGS1 1214/4885SLC7A11 4767/4885
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 SLC7A5 1308/4885PTGS1 946/4885SLC7A11 1200/4885
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK SLC7A5 1976/4885PTGS1 1685/4885SLC7A11 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.